Number and volume of Gd-enhancing lesions declined by 44%, (p<0.0001) and 41% (p=0.0018), respectively. Treatment was well tolerated.
Statins might be beneficial for MS patients as monotherapy or as an add-on to established disease modifying drugs. As the evidence of the benefit of statins in MS is currently insufficient, large controlled clinical trials are needed. The first of these trials is about to start.
Furthermore, in vitro experiments with human immune cells have documented an immunomodulatory mode of action of statins comparable to that of interferon (IFN)-beta. An open label clinical trial assessing simvastatin in MS revealed a significant decrease in the number and volume of new MRI lesions and a favourable safety profile.
HopefulDoc wrote:Can any one out there tell me how long it took to start seeing improvemements in your case.
HopefulDoc wrote:Also - can anyone lead me to info on results of human trials. I am going to need SOMETHING on human trials to give my primary physician when I ask her for a RX.
Remember that lipitor is sold on the shelf in England
Users browsing this forum: No registered users